Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1–211. DOI:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clinics. 2019;37(4):631–649.
   PubMed Web of Science ®Google Scholar
• Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559–575.
   PubMedGoogle Scholar
• Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80.
   PubMedGoogle Scholar
• Kind P, Lafata JE, Matuszewski K, et al. The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health. 2009;12 Suppl 1:S27–30.
   PubMed Web of Science ®Google Scholar
• Brown JS, Neumann PJ, Papadopoulos G, et al. Migraine frequency and health utilities: findings from a multisite survey. Value Health. 2008;11(2):315–321. DOI:10.1111/j.1524-4733.2007.00246.x
   PubMed Web of Science ®Google Scholar
• Brazier J, Connell J, Papaioannou D, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18:1–180.
   PubMed Web of Science ®Google Scholar
• van Hout BA, Shaw J. Mapping EQ-5D-3L to EQ-5D-5L. Value Health. 2021;24(9):1285–1293.
   PubMed Web of Science ®Google Scholar
• Johnston KM, L’Italien G, Popoff E, et al. Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant. Adv Ther. 2021;38(10):5209–5220. DOI:10.1007/s12325-021-01897-2
   PubMed Web of Science ®Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–832. DOI:10.1177/0333102418758283
   PubMed Web of Science ®Google Scholar
• Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026–1044. DOI:10.1177/0333102420941839
   PubMed Web of Science ®Google Scholar
• Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409–421. DOI:10.1111/j.1526-4610.2011.01997.x
   PubMed Web of Science ®Google Scholar
• Gillard PJ, Devine B, Varon SF, et al. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health. 2012;15(3):485–494. DOI:10.1016/j.jval.2011.12.007
   PubMed Web of Science ®Google Scholar
• Jönsson L, SA R, Kymes S, et al., editors. Disease-specific quality-of-life measures mapped to the EQ-5D in a chronic disorder with recurrent attacks: analysis of the deliver trial in patients with migraine. ISPOR Europe: Vienna Austria. 2022 Dec 11.
   Google Scholar
• Sacco S, Amin F, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67.
   PubMed Web of Science ®Google Scholar
• Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597–607. DOI:10.1016/S1474-4422(22)00185-5
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Barbanti P, Lambru G, et al. Eptinezimab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Euro J Of Neurology. 2023;30:1089–1098.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache. 2021;61(5):766–776. DOI:10.1111/head.14120
   PubMed Web of Science ®Google Scholar
• Winner PK, McAllister P, Chakhava G, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348–2356. DOI:10.1001/jama.2021.7665
   PubMed Web of Science ®Google Scholar
• Barbanti P, Goadsby PJ, Lambru G, et al. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain. 2022;23(1):153. DOI:10.1186/s10194-022-01521-w
   PubMed Web of Science ®Google Scholar
• Wang X, Wen D, He Q, et al. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain. 2022;23(1):105. DOI:10.1186/s10194-022-01472-2
   PubMed Web of Science ®Google Scholar
• Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the migraine-specific quality of life questionnaire. Headache. 1998;38(4):295–302. DOI:10.1046/j.1526-4610.1998.3804295.x
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). 2018 . Erenumab for preventing migraine [ID1188] - Single Technology Appraisal Document; [cited 2020 Mar 27]; Available from: https://www.nice.org.uk/guidance/ta682/documents/committee-papers-3
   Google Scholar
• Buse DC, Winner PK, Charleston L, et al. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. J Headache Pain. 2022;23(1):29. DOI:10.1186/s10194-022-01387-y
   PubMed Web of Science ®Google Scholar
• Streiner DL. Finding our way: an introduction to path analysis. Can J Psychiatry. 2005;50(2):115–122.
   PubMed Web of Science ®Google Scholar
• Mahon R, Lang A, Vo P, et al. Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics. 2021;39(3):357–372. DOI:10.1007/s40273-020-00996-2
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Lipton RB, et al. Benefits beyond headache days with onabotulinumtoxinA treatment: a pooled PREEMPT analysis. Pain Ther. 2020;9:683–694.
   PubMed Web of Science ®Google Scholar
• Young M, Ng S, Mellick G, et al. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson’s disease. Qual Life Res. 2013;22:1065–1072.
   PubMed Web of Science ®Google Scholar
• Purba F, Anggriani Y, Murtini T. EQ-5D-5L in Schizophrenia: differences between patients and nurses’ reports. Health Qual Life Outcomes. 2021;19:240–248.
   PubMed Web of Science ®Google Scholar
• Moore A, Young C, Hughes D. Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor neuron disease. Value Health. 2018;21(11):1322–1329.
   PubMed Web of Science ®Google Scholar
• Broderick JE, Stone AA, Calvanese P, et al. Recalled pain ratings: a complex and poorly defined task. J Pain. 2006;7(2):142–149. DOI:10.1016/j.jpain.2005.09.012
   PubMed Web of Science ®Google Scholar
• Stull DE, Leidy NK, Parasuraman B, et al. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929–942. DOI:10.1185/03007990902774765
   PubMed Web of Science ®Google Scholar